Organon India appoints Vivek Soares As its New Country Lead For India And South Asia

 Organon India announces the appointment of Vivek Soares as its new Country Lead for India and South Asia, commencing on June 1st, 2024.

Soares will take the reins from Anjan Sen, who will retire after 35 years in the biopharmaceutical sector, which includes 11 years with MSD and Organon.  Anjan was pivotal in setting up Organon’s operations in India and the neighbouring markets in South Asia while building the commercial organization and business plan for India to be a long-term growth driver in the region.

Soares brings over 20 years of experience in the biopharmaceutical industry, having held numerous leadership roles at both country and regional levels. He has successfully led diverse teams across markets, developed and executed successful strategies, to increase sales and profitability, while building future capabilities.

Prior to joining Organon India, Vivek served as Strategic Partnerships & Business Development Lead for Organon Thailand. He has also held positions such as Director, Fertility Business Unit in Asia Pacific, Head of Tender & Key Account in Vietnam, and Senior Marketing Manager for Women's Health covering India, Sri Lanka, and Nepal.

"I am thrilled to have Vivek on board as the new Country Lead for India and South Asia, and as a member of the Organon Asia Pacific leadership Team. Organon’s markets across Asia Pacific is home to over one quarter of the world’s female population, and Vivek’s extensive experience in supporting the health of women across this region provides a strong foundation to also drive growth and success in India," said Andreas Daugaard Jorgensen, Managing Director Organon Asia Pacific.

Commenting on his appointment, Vivek said, “I’m excited to join Organon as the company embarks on its next exciting chapter and extend my gratitude to Anjan Sen who has been pivotal in setting up Organon’s operations in India and the neighbouring markets in South Asia. I’m looking forward to working with our partners and health care professionals to deliver on Organon’s mission to create a healthier future for every woman every day.”

About Organon: Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.